Clinical trial links oncolytic immunoactivation to survival in glioblastoma
Alexander Ling, Isaac H. Solomon, Ana Montalvo Landivar, Hiroshi Nakashima et autres
Abstract Immunotherapy failures can result from the highly suppressive tumour microenvironment that characterizes aggressive forms of cancer such as recurrent glioblastoma (rGBM) 1,2 . Here we report the results of a first-in-human phase I trial in 41 patients with rGBM who were …
us, il (code pays fourni par la source)